The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

💼 Finance & Business
📡 3 sourcesForbes Business, Inc.com, CNBC Business
Summary

As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.

Visit the original source for the full article

🌐 Translate to:
More from 💼 Finance & Business →